Several estrogen-inhibiting therapies are currently available for ER-α/PgR-positive breast cancer, which are largely divided into two categories: anti-ER therapy and therapy inhibiting estrogen production (Figure 5) [1]. The gene discussed is PGR; the disease is breast cancer.